The UAE’s longevity and biohacking market is booming. Peptide therapies, IV infusions, biological-age tests, supplement stacks, full-body scans, wearables and GLP-1 drugs are all available in Dubai and Abu Dhabi’s rapidly expanding wellness clinic sector, and a growing number of UAE residents are spending significant sums on protocols that promise to slow ageing, optimise performance and extend healthy life. Khaleej Times this week asked leading UAE doctors to separate the evidence from the hype, and the answers are both clarifying and, in places, surprising. The strongest evidence for extending healthspan, the years you live well rather than just the years you live, remains remarkably unglamorous. Cardiovascular fitness, strength training, adequate sleep, controlled blood pressure and cholesterol, managed blood sugar and not smoking are the interventions with the most robust data behind them. Most of what the booming longevity market is selling is addition on top of that foundation, not a replacement for it.
Dr Reem Almarzooqi, a specialist at a leading UAE wellness clinic, told Khaleej Times that exosome therapies, certain peptides, high-dose NAD+ infusions marketed as cellular age reversal and biological-age supplement stacks sit on evidence levels that most patients would never accept if they actually saw the source data. That assessment is consistent with the international clinical literature: the global biohacking market is valued at approximately $33 billion and growing, but the clinical validation for most of the interventions driving that market lags significantly behind the marketing. Cleveland Clinic Abu Dhabi‘s specialists similarly urged caution, noting that many of the most expensive interventions available in the UAE wellness market have not been tested in rigorous randomised controlled trials with meaningful endpoint data.
“The strongest evidence for extending healthy life remains straightforward: cardiovascular fitness, strength training, adequate sleep, healthy blood pressure and cholesterol, good blood sugar control and avoiding smoking. Most of what the longevity market is selling is useful at best and expensive hype at worst without that foundation in place.”
— UAE Longevity Medicine Specialists, Khaleej Times (khaleejtimes.com, August 2026)
What UAE Doctors Say Actually Works
The interventions that UAE doctors consistently endorse as having strong clinical evidence are a shorter list than the longevity market would suggest. GLP-1 receptor agonists, the class of drugs that includes semaglutide and which has reshaped obesity treatment globally, are receiving increasing attention in the longevity context not primarily for weight loss but for their cardiovascular outcome data. The evidence that GLP-1 drugs reduce cardiovascular events, systemic inflammation and insulin resistance represents a different standard of clinical validation from most of the interventions dominating the longevity market, and UAE specialists are beginning to discuss their potential longevity applications explicitly rather than limiting the conversation to obesity and diabetes management.
Wearables that track meaningful biomarkers, particularly continuous glucose monitors, heart rate variability monitors and sleep quality trackers, receive qualified endorsement from UAE clinicians because they generate data that can inform genuinely useful behavioural changes rather than just providing numbers to look at. The qualification is important: the data only produces value if it changes behaviour, and the evidence that wearable-generated data changes health outcomes at a population level is still accumulating. Personalised nutrition based on advanced blood panels, including hormone levels, inflammatory markers, metabolomics and biological age assessments, is another area where UAE specialists see genuine value when the testing is done rigorously and the interpretation is led by qualified clinicians rather than wellness marketers.
What the Longevity Boom Means for UAE Residents and Businesses
For UAE residents navigating the longevity market, the doctors’ verdict suggests a simple framework: invest first in the unglamorous basics, cardiovascular fitness, strength, sleep and metabolic health, before spending on the sophisticated interventions that require those foundations to work. A peptide protocol or an IV infusion programme delivered to someone who does not exercise consistently, sleeps poorly and eats badly is not going to produce meaningful longevity outcomes, regardless of what the clinic’s marketing says. For businesses in the UAE wellness sector, the Khaleej Times analysis is a prompt to think carefully about the evidence base behind the services being offered and the liability that comes with marketing outcomes that the clinical literature does not support. The UAE’s regulatory environment for wellness and medical services is becoming more sophisticated, and the businesses that invest in clinical rigor now will be better positioned as that regulatory sophistication increases.
“GLP-1 receptor agonists belong in the longevity conversation now. Not because of weight loss, but because we have cardiovascular outcome data. This represents a different standard of evidence from many of the interventions dominating the longevity market, and UAE clinicians are beginning to discuss their potential longevity applications explicitly.”
— UAE Longevity Medicine Specialist (Khaleej Times, August 2026)
